AKTTHR308 as a marker of PI3K activation was measured in cells from a subset of chronic lymphocytic leukaemia patients with circulating lymphocytes and was observed to be reduced by >90% following dosing, demonstrating target inhibition. This evidence concerns the gene PIK3CD and B-cell chronic lymphocytic leukemia.